Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL19259630

N#CC1(CNC2CCNCC2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.37
HRH3 Q9Y5N1 2/20 0.37
DPP7 Q9UHL4 1/20 0.37
EPHX1 P07099 2/20 0.37
KDM1A O60341 2/20 0.35
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CACNA1B Q00975 1/20 0.31
POLB P06746 1/20 0.31
CDK4 P11802 1/20 0.31
CDK2 P24941 1/20 0.31
CDK5 Q00535 1/20 0.31
CSF1R P07333 1/20 0.31
CYP2C9 P11712 1/20 0.31
CTSL P07711 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19013818 0.85 KDM1A (0.40) DPP7EPHX1KDM1A
SCHEMBL24890877 0.74 KDM1A (0.45) KDM1AMEN1KMT2A
Trifluoroacetic Acid SCHEMBL25319079 0.73 KDM1A (0.32) KDM1A
Trifluoroacetic Acid SCHEMBL5014957 0.73 SLC6A2 (0.43) HRH4HRH3KDM1A
Trifluoroacetic Acid SCHEMBL6475658 0.70 GABRA5 (0.38) HRH4HRH3KDM1ACHRM3
Trifluoroacetic Acid SCHEMBL5785638 0.69 EPHX1 (0.47) HRH4HRH3EPHX1KDM1ACACNA1B
Trifluoroacetic Acid SCHEMBL334563 0.68 GABRP (0.39) HRH4HRH3EPHX1KDM1ACACNA1B
Trifluoroacetic Acid SCHEMBL27731525 0.68 EPHX1 (0.45) HRH4HRH3EPHX1CACNA1BPOLB
Trifluoroacetic Acid SCHEMBL5040926 0.68 BCHE (0.47) HRH4HRH3
Trifluoroacetic Acid SCHEMBL27736416 0.67 GNAI3 (0.39) HRH4HRH3DPP7EPHX1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795170-B2 Therapeutic compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2023-10-24 US disclosed
EP-3416967-B1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2022-02-09 EP disclosed
US-20210009599-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-01-14 US disclosed
EP-3416967-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF H. Hoffnabb-La Roche Ag (CH) 2018-12-26 EP disclosed
US-20180354959-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-12-13 US disclosed
WO-2017140825-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795170-B2 Therapeutic compounds, compositions and methods of use thereof JAK2, JAK1, JAK3 HRH4 3044/4885HRH3 2765/4885DPP7 564/4885
US-20180354959-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF JAK2, JAK1, JAK3 HRH4 2440/4885HRH3 2214/4885DPP7 524/4885
US-20210009599-A1 THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF JAK2, JAK1, JAK3 HRH4 3044/4885HRH3 2765/4885DPP7 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.